Clinical

Dataset Information

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer


ABSTRACT: The PIPAC NAL-IRI study is designed to examine the maximal tolerated dose of nanoliposomal irinotecan (Nal-IRI, Onivyde) administered with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC), in a monocentric, phase I trial.

DISEASE(S): Gastrointestinal Neoplasms,Carcinoma,Colorectal Cancer,Pancreatic Cancer,Appendiceal Neoplasms,Peritoneal Carcinomatosis,Small Bowel Cancer,Peritoneal Metastases,Peritoneal Neoplasms,Neoplasm Metastasis,Appendix Cancer,Bile Duct Neoplasms,Gastric Cancer,Bile Duct Cancer,Colorectal Neoplasms,Pancreatic Neoplasms

PROVIDER: 2709176 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR